Lambers WM, Westra J, Bootsma H, et al. - This study was undertaken to investigate whether hydroxychloroquine suppresses interferon-inducible genes and B cell activating factor in patients with incomplete and new-onset systemic lupus erythematosus. Researchers enrolled patients with incomplete systemic lupus erythematosus (iSLE; antinuclear antibody titer ≥ 1:80, symptoms < 5 years, ≥ 1 objectified clinical American College of Rheumatology or SLE International Collaborating Clinics criteria), or new-onset, mild SLE when hydroxychloroquine (HCQ) treatment was started for clinical reasons. The results showed that in patients with iSLE or new-onset SLE, HCQ suppresses interferon score and B cell activating factor levels, and there is a trend towards lowering IP-10 levels. This might support the hypothesis that HCQ could influence disease progression as these biomarkers are early mediators in SLE. Nevertheless, there is a need for prospective research with a larger sample size and longer follow-up.